InMed Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 13, 2024
INM$15.56+17.8%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Interim Balance Sheets
| December 31, | |||
|---|---|---|---|
| 2023 · June 30, | |||
| Note | (unaudited) | 2023 | |
| $ · $ | |||
| ASSETS | |||
| Current | |||
| Cash and cash equivalents | 9,534,922 | 8,912,517 | |
| Short-term investments | 44,462 | 44,422 | |
| Accounts receivable, net | 372,870 | 260,399 | |
| Inventories | 3 | 744,839 | 1,616,356 |
| Prepaids and other current assets | 1,112,977 | 498,033 | |
| Total current assets | 11,810,070 | 11,331,727 | |
| Non-Current | |||
| Property, equipment and ROU assets, net | 4 | 1,481,102 | 723,426 |
| Intangible assets, net | 5 | 1,864,292 | 1,946,279 |
| Other assets | 100,000 | 104,908 | |
| Total Assets | 15,255,464 | 14,106,340 | |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |||
| Current | |||
| Accounts payable and accrued liabilities | 6 | 1,287,623 | 1,608,735 |
| Current portion of lease obligations | 9 | 364,190 | 375,713 |
| Deferred rent | 28,656 | 16,171 | |
| Total current liabilities | 1,680,469 | 2,000,619 | |
| Non-current | |||
| Lease obligations, net of current portion | 9 | 802,784 | 15,994 |
| Total Liabilities | 2,483,253 | 2,016,613 | |
| Commitments and Contingencies (Note 11) | |||
| Shareholders’ Equity | |||
| Common shares, no par value, unlimited authorized shares: | |||
| 5,667,970 (June 30, 2023 - 3,328,191) issued and outstanding | 7 | 79,936,633 | 77,620,252 |
| Additional paid-in capital | 7, 8 | 38,122,231 | 35,741,115 |
| Accumulated deficit | (105,415,222) | (101,400,209) | |
| Accumulated other comprehensive income | 128,569 | 128,569 | |
| Total Shareholders’ Equity | 12,772,211 | 12,089,727 | |
| Total Liabilities and Shareholders’ Equity | 15,255,464 | 14,106,340 | |
| Related Party Transactions (Note 12) | |||
| Subsequent Events (Note 13) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.